The primary goal of the Biostatistics Shared Resource (BSR) is to provide biostatistics support to basic scientists, clinical researchers, and population scientists who are conducting cancer research at OHSU. In addition to providing biostatistics support to individual researchers, the BSR also provides such support to other shared resources of the OHSU Cancer Institute (Cl). The BSR strives to enhance the scientific quality and statistical sophistication of cancer research through tailored professional consultation at all levels and stages of cancer research. By leveraging strong Cl institutional commitment, CCSG, and project-specific grant support, the BSR provides biostatistics support to cancer researchers in a cost-efficient manner. Specific services include: 1) study and experimental design; 2) sample size and power analysis; 3) statistical analysis plan; 4) data analysis; 5) manuscript preparation and review; 6) development and implementation of statistical protocols for high-throughput cores; 7) grant submission assistance; 8) development of clinical research protocols; 9) institutional clinical research support, including scientific review and data monitoring, and; 10) training and education. The BSR emphasizes research collaboration at the earliest stage possible as most productive research is conducted under a collaborative research environment.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA069533-09
Application #
7109839
Study Section
Subcommittee G - Education (NCI)
Project Start
2005-08-05
Project End
2010-05-31
Budget Start
2005-08-05
Budget End
2006-05-31
Support Year
9
Fiscal Year
2005
Total Cost
$61,990
Indirect Cost
Name
Oregon Health and Science University
Department
Type
DUNS #
096997515
City
Portland
State
OR
Country
United States
Zip Code
97239
Smith, Nicholas R; Swain, John R; Davies, Paige S et al. (2018) Monoclonal Antibodies Reveal Dynamic Plasticity Between Lgr5- and Bmi1-Expressing Intestinal Cell Populations. Cell Mol Gastroenterol Hepatol 6:79-96
Langer, E M; Kendsersky, N D; Daniel, C J et al. (2018) ZEB1-repressed microRNAs inhibit autocrine signaling that promotes vascular mimicry of breast cancer cells. Oncogene 37:1005-1019
Sorace, Anna G; Partridge, Savannah C; Li, Xia et al. (2018) Distinguishing benign and malignant breast tumors: preliminary comparison of kinetic modeling approaches using multi-institutional dynamic contrast-enhanced MRI data from the International Breast MR Consortium 6883 trial. J Med Imaging (Bellingham) 5:011019
Medler, Terry R; Murugan, Dhaarini; Horton, Wesley et al. (2018) Complement C5a Fosters Squamous Carcinogenesis and Limits T Cell Response to Chemotherapy. Cancer Cell 34:561-578.e6
Kelley, Katherine A; Wieghard, Nicole; Chin, Yuki et al. (2018) MiR-486-5p Downregulation Marks an Early Event in Colorectal Carcinogenesis. Dis Colon Rectum 61:1290-1296
Davare, Monika A; Henderson, Jacob J; Agarwal, Anupriya et al. (2018) Rare but Recurrent ROS1 Fusions Resulting From Chromosome 6q22 Microdeletions are Targetable Oncogenes in Glioma. Clin Cancer Res 24:6471-6482
Kurtz, Stephen E; Eide, Christopher A; Kaempf, Andy et al. (2018) Dual inhibition of JAK1/2 kinases and BCL2: a promising therapeutic strategy for acute myeloid leukemia. Leukemia 32:2025-2028
Sehrawat, Archana; Gao, Lina; Wang, Yuliang et al. (2018) LSD1 activates a lethal prostate cancer gene network independently of its demethylase function. Proc Natl Acad Sci U S A 115:E4179-E4188
Watson, Spencer S; Dane, Mark; Chin, Koei et al. (2018) Microenvironment-Mediated Mechanisms of Resistance to HER2 Inhibitors Differ between HER2+ Breast Cancer Subtypes. Cell Syst 6:329-342.e6
Li, Bingbing X; Chen, Jingjin; Chao, Bo et al. (2018) Anticancer Pyrroloquinazoline LBL1 Targets Nuclear Lamins. ACS Chem Biol 13:1380-1387

Showing the most recent 10 out of 277 publications